Dr. Carol Aghajanian, MD – New York, NY
Sophia Aguilar Overview of Dr. Aghajanian
Dr. Carol Aghajanian is the Chief of Gynecologic Medical Oncology at Memorial Sloan Kettering Cancer Center and Professor of Medicine, Weill Cornell Medical College, New York, NY.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1992 - 1995
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 1989 - 1992
State University of New York Downstate Medical Center College of MedicineClass of 1989, MD, Cum Laude, Alpha Omega Alpha
Boston UniversityBA, Biology, Summa Cum Laude, Phi Beta Kappa, 1981 - 1985
Certifications & Licensure
FL State Medical License 2021 - Present
NJ State Medical License 2019 - 2025
NY State Medical License 1990 - 2024
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2011-2014
- Top Doctors: New York Metro Area Castle Connolly, 2009-2014
- America's Top Doctors for Cancer Castle Connolly, 2010-2013
Clinical Trials
Publications & Presentations
PubMed
A phase 2 trial of zanidatamab in HER2-overexpressed advanced endometrial carcinoma and carcinosarcoma (ZW25-IST-2).
Chui, M., Zhou, Q., Iasonos, A., Cohen, S., Lumish, M., Sarasohn, D., Friedman, C., Grisham, R., Konner, J., Kyi, C., Rubinstein, M., Troso-Sandoval, T., Aghajanian, C...> ;Gynecologic Oncology. 2024 Jan 22Mesonephric and mesonephric-like adenocarcinomas of gynecologic origin: A single-center experience with molecular characterization, treatment, and oncologic outcomes.
White, C., Iasonos, A., Selenica, P., Weigelt, B., Praiss, A., Zivanovic, O., Chi, D., Abu-Rustum, N., Aghajanian, C., Girshman, J., Park, K., Grisham, R.> ;Gynecologic Oncology. 2024 Jan 20Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146.
Makker, V., Taylor, M., Aghajanian, C., Cohn, A., Brose, M., Simone, C., Cao, Z., Suttner, L., Loboda, A., Cristescu, R., Jelinic, P., Orlowski, R., Dutta, L., Matsui,...> ;Journal for Immunotherapy of Cancer. 2024 Jan 19- Join now to see all
Journal Articles
A Phase 1 Dose-Escalation Study of Intraperitoneal Cisplatin, intravenous/intraperitoneal Paclitaxel, Bevacizumab, and Olaparib for Newly Diagnosed Ovarian Cancer
Karen A Cadoo, Roisin E O'Cearbhaill, Dmitriy Zamarin, Paul J Sabbatini, William P Tew, Carol Aghajanian, Jason A Konner, Gynecologic OncologyMaintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Kathleen Moore, Paul DiSilvestro, Carol Aghajanian, The New England Journal of Medicine
Lectures
Targeted Agents: Finding the Mark
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018Evaluation of rucaparib in platinum-sensitive recurrent ovarian carcinoma (rOC) in patients (pts) with or without residual bulky disease at baseline in the ARIEL3 study.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018Scientific and Clinical Update in Gynecologic Oncology
Jefferson Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania - 5/3/2013
Press Mentions
Combination of Endometrial Cancer Drugs May Prolong Lives of WomenMarch 31st, 2023
New Drug Combo Buys More Time for Advanced Endometrial Cancer PatientsMarch 28th, 2023
For Advanced Endometrial Cancer, Chemotherapy plus Immunotherapy Improves OutcomesMarch 28th, 2023
- Join now to see all
Professional Memberships
Hospital Affiliations
Insurance Accepted
Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
GHI PPO
Great West PPOHumana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO- Please verify your coverage with the provider's office directly when scheduling an appointment
